Abstracts Archive - Page 4 of 2616 - ACR Meeting Abstracts

Abstract Number: 052 • 2026 Pediatric Rheumatology Symposium
Case Series: Treatment of Refractory Lung Disease in Systemic Juvenile Idiopathic Arthritis with Cyclophosphamide and Rituximab Combination Therapy
William Freeman¹, Randy Cron² and Eileen Rife³, ¹Zucker School of Medicine at Hofstra University, Bellerose, NY, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama Birmingham, Vestavia Hills, AL
Background/Purpose: Systemic juvenile idiopathic arthritis-associated lung disease (sJIA-LD) is a rare, potentially fatal complication of sJIA, often accompanied by pulmonary hypertension (PH) and macrophage activation…
Abstract Number: 026 • 2026 Pediatric Rheumatology Symposium
Treatment strategies for articular flares in JIA patients receiving biologic therapy
Jonatan zalcman, Yoel Levinsky, Liora Harel, Ruth Livny and gil amarilyo, Schneider Children's medical center of Israel
Background/Purpose: Biologic agents form the cornerstone of therapy for Juvenile Idiopathic Arthritis (JIA); however, the optimal management of flares that occur during ongoing treatment remains…
Abstract Number: 003 • 2026 Pediatric Rheumatology Symposium
Dysregulated Macrophage–Fibroblast Crosstalk Identified by Single-Cell RNA-seq in Juvenile Systemic Scleroderma Skin
Aneri Shethji¹, Theresa Hutchins¹, Anwesha Sanyal¹ and Kathryn Torok², ¹UPMC Childrens Hospital of Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Juvenile systemic scleroderma (jSSc) is a rare autoimmune disease characterized by progressive fibrosis and vascular dysfunction. Although jSSc shares important clinical features with adult…
Abstract Number: 045 • 2026 Pediatric Rheumatology Symposium
Genotypes and Clinical Phenotypes of Monogenic Autoinflammatory Disorders in Michigan
Ryan Mitacek¹, Veronica Kwiatkowski¹ and Basil Fathalla², ¹Children's Hospital of Michigan, Central Michigan University College of Medicine, ²Children's Hospital of Michigan, Detroit, MI
Background/Purpose: Data regarding monogenic systemic autoinflammatory disorders (SAID) from the USA is scarce. Our study aims to report the spectrum of SAID and detail unique…
Abstract Number: 023 • 2026 Pediatric Rheumatology Symposium
Screening Tools for Spondyloarthropathies among Patients with Inflammatory Bowel Disease: A Scoping Review
Hanul (Erica) Park¹, Ellen Kuenzig², Fatima Mela³, Emaan Awan⁴, Sherry Rohekar⁵, Eileen Crowley¹ and Roberta A Berard⁶, ¹London Children's Hospital, ON, Canada, ²Schulich- University of Western Ontario, ON, Canada, ³Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry at Western University, ON, Canada, ⁴Western University, ON, Canada, ⁵University of Western Ontario - London, London, ON, Canada, ⁶London Health Sciences Centre, London, ON, Canada
Background/Purpose: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a systemic chronic inflammatory disease of the gastrointestinal tract where extraintestinal manifestations (EIMs)…
Abstract Number: 025 • 2026 Pediatric Rheumatology Symposium
Longitudinal Single Cell Transcriptomic Analysis of Type I and II Interferon (IFN) Response Genes (IRG) in Refractory Juvenile Dermatomyositis (JDM) Patients with Baricitinib Treatment
Jessica Simpson¹, Vicky Chen², Adeline Chin³, Ujana Zajmi³, Amy Kaneshiro³, Megan Darrell⁴, Stephen Brooks³, Robert Colbert⁵, Lisa Rider⁶, Stefania Dell’Orso³, Faiza Naz³ and Hanna Kim⁷, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)/National Institutes of Health (NIH), ²National Institute of Allergy and Infectious Diseases (NIAID)/ National Institutes of Health (NIH), Frederick, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) / National Institutes of Health (NIH), ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) / National Institutes of Health (NIH), NY, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) / National Institutes of Health (NIH), Rockville, MD, ⁶National Institute of Environmental Health Sciences (NIEHS)/National Institutes of Health (NIH), ⁷National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS) / National Institutes of Health (NIH)
Background/Purpose: JDM is a rare heterogenous autoimmune condition. Pathogenesis is incompletely understood, though dysregulated type I/II IFN signaling is well-documented. Patients with refractory JDM had…
Abstract Number: 021 • 2026 Pediatric Rheumatology Symposium
Medication Changes and Lung Disease Activity in Systemic JIA: Six-Month Follow-Up of CARRA Registry SJIA-LD Cohort
Grant Schulert¹, Eileen Rife², Mary Ellen Riordan³, Alan Russell⁴, Mei-Sing Ong⁵, Esraa Eloseily⁶, Lexi Auld⁷, Yukiko Kimura⁸, and CARRA Registry SJIA-LD Cohort Investigators ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²University of Alabama Birmingham, Vestavia Hills, AL, ³Hackensack University Medical Center, Westwood, NJ, ⁴Duke Clinical Research Institute, NC, ⁵Boston Children's Hospital, Boston, MA, ⁶UT Southwestern Children's Medical Center, Dallas, TX, ⁷Cincinnati Children's Hospital Medical Center, OH, ⁸Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Lung disease is a severe and potentially fatal complication of systemic juvenile idiopathic arthritis (SJIA-LD). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry…
Abstract Number: 030 • 2026 Pediatric Rheumatology Symposium
Musculoskeletal and Nail Ultrasound Findings in Children with Psoriasis: A Case-Control Study
Laura Nedorezov¹, Pinar Avar-Aydin², Tracy Ting³, Cheryl Bayart⁴, Amy Cassedy⁵ and Patricia Vega-Fernandez³, ¹Cleveland Clinic Children's, ²Division of Rheumatology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, TR, ³Division of Rheumatology, Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, ⁵Division of Biostatistics and Epidemiology, Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) is a…
Abstract Number: 005 • 2026 Pediatric Rheumatology Symposium
Magnetic Resonance Enterography Detected Sacroiliitis in Pediatric Crohn’s Disease: A Retrospective Cohort Study
Aaisham Ali¹, Vishal Kalia², Ian Ross², Luke Daichendt³, Julia Sawicka⁴, Michael R Miller⁵, Sarah Wells⁶, Eileen Crowley⁶ and Roberta A Berard⁷, ¹Schulich School of Medicine & Dentistry, Pediatrics, London Health Sciences Centre, London, ON, Canada, ²Department of Medical Imaging, Western University, ³Schulich School of Medicine & Dentistry, Western University, ⁴Western University, ⁵Department of Pediatrics, Children's Hospital, London Health Sciences Centre, ⁶London Children's Hospital, ON, Canada, ⁷London Health Sciences Centre, London, ON, Canada
Background/Purpose: Musculoskeletal (MSK) manifestations are amongst the most common extraintestinal manifestations (EIMs) in pediatric Crohn’s disease (CD). MSK EIMs contribute to reduced quality of life…
Abstract Number: 014 • 2026 Pediatric Rheumatology Symposium
Bone Microarchitecture Impairment in Juvenile Systemic Lupus Erythematosus Patients: A Comparative Study
BEATRIZ ROSA¹, Melissa Fraga², Ana Sakamoto³, Erica Barbosa⁴, Jade Fernandez⁴, Marcelo Pinheiro⁵ and Maria Teresa Terreri⁶, ¹UNIVERSIDADE FEDERAL DE SO PAULO, So Paulo, Brazil, ²Universidade Federal de So Paulo, So Paulo, So Paulo, Brazil, ³Federal University of So Paulo (UNIFESP), So Paulo, Brazil, ⁴UNIFESP/ EPM, Sao Paulo, Sao Paulo, Brazil, ⁵UNIFESP/ EPM, So Paulo, Brazil, ⁶UNIFESP, So Paulo, So Paulo, Brazil
Background/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a multisystem inflammatory disease frequently associated with bone mass loss. This reduction can be assessed through bone mineral…
Abstract Number: 020 • 2026 Pediatric Rheumatology Symposium
Building Consensus on Key Research Domains and Research Topics in Childhood-onset Neuropsychiatric Lupus: An International Prioritization Initiative
Ekemini Ogbu¹, Martha Rodriguez², Alexandra Theisen³, Simone Appenzeller⁴, Emily Beil⁵, Onengiya Harry⁶, Ryan Kammeyer⁷, Natoshia Cunningham⁸, Kristen Fisher⁹, Marisa Klein-Gitelman¹⁰, Monica Banks¹¹, Eyal Muscal¹², Sefi Kronenberg¹³, Paige Seegan¹⁴, Lawrence Ng¹⁵, Marietta DeGuzman¹², Mckenna Bowes¹⁶, Kiana Johnson¹⁷, Y. Ingrid Goh¹⁸, Eve Smith¹⁹, Katerina Bouchalova²⁰, Lea Höfel²¹, Jainish Patel¹, Mekibib Altaye²², Rashmi Sahay²³, Susanne Benseler²⁴, Hermine Brunner¹ and Andrea Knight²⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Riley Hospital For Children At Indiana University, Carmel, IN, ³Riley Hospital for Children at Indiana University, ⁴Universidade Estadual de Campinas, Brazil, ⁵Atrium Health, Levine Children's Hospital, ⁶Atrium Health Wake Forest School of Medicine, ⁷Departments of Pediatrics and Neurology, University of Colorado School of Medicine, Aurora, CO, ⁸Michigan State University, Grand Rapids, ⁹Baylor College of Medicine, ¹⁰Ann & Robert H. Lurie Children's Hospital Chicago, Chicago, IL, ¹¹Family Advisory Council, Neuropsychiatric Workgroup, Childhood Arthritis and Rheumatology Research Alliance, ¹²Baylor College of Medicine, houston, TX, ¹³The Hospital for Sick Children and University of Toronto, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD, ¹⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ¹⁶West Virginia University School of Medicine, Morgantown, WV, ¹⁷East Tennessee State Universityy, TN, ¹⁸The Hospital for Sick Children, ¹⁹University of Glasgow, Glasgow, Scotland, United Kingdom, ²⁰Palacky University Olomouc, Olomouc, Czech Republic, ²¹Pediatric clinic Garmisch-Partenkirchen / Germany, Garmisch-Partenkirchen, Bayern, Germany, ²²Cincinnati Children's Hospital, Cincinnati, ²³Cincinnati Children's Hospital Medical Center, OH, ²⁴Children’s health Ireland, Dublin, Dublin, Ireland, ²⁵Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a major end-organ manifestation of childhood-onset systemic lupus erythematosus (cSLE) and is poorly understood. High-quality, collaborative and patient-centered…
Abstract Number: 037 • 2026 Pediatric Rheumatology Symposium
Off-the-Shelf Anti-CD19 CAR T-cell Therapy with Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
Natalie Shiff¹, Jennifer Medlin², Parastoo Fazeli³, Shirley Pang⁴, Sheetal Desai⁵, Andrew BitMansour⁶, Claudette Bethune¹, Debra Zack⁷, Rebecca Elstrom⁸, Trever Greene¹, Lilly Wong¹, Carol Wong¹, Beatrice Ferguson¹ and Vaneet Sandhu¹, ¹Fate Therapeutics, Inc., San Diego, CA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Minnesota, ST PAUL, MN, ⁴Providence Medical Foundation, Fullerton, CA, ⁵University of California Irvine, Orange, CA, ⁶Fate Therapeutics, Inc., San Carlos, CA, ⁷Fate Therapeutics, Inc., Solana Beach, CA, ⁸Fate Therapeutics, Inc.
Background/Purpose: Childhood-onset systemic lupus erythematosus (SLE) is typically more severe than adult-onset disease, with higher morbidity, organ damage, and mortality. Despite this, pediatric drug trials…
Abstract Number: 043 • 2026 Pediatric Rheumatology Symposium
Challenges of Cognitive Screening and Formal Neuropsychological Evaluation in Youth with Childhood-Onset Systemic Lupus Erythematosus: A Survey of CARRA Providers
Ryan Kammeyer¹, Martha Rodriguez², Andrea Knight³, Rebecca Sadun⁴, Jeffrey Bennett⁵, Robert Fuhlbrigge⁶, Christa Hutaff-Lee⁵ and Ekemini Ogbu⁷, ¹Departments of Pediatrics and Neurology, University of Colorado School of Medicine, Aurora, CO, ²Riley Hospital For Children At Indiana University, Carmel, IN, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Duke University School of Medicine, Durham, NC, ⁵University of Colorado School of Medicine, ⁶University of Colorado, Aurora, CO, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Cognitive dysfunction (CD) occurs in 30-60% of youth with childhood-onset systemic lupus erythematosus (cSLE), and negatively impacts medical care, socioeconomic achievement, and quality of…
Abstract Number: 015 • 2026 Pediatric Rheumatology Symposium
Obinutuzumab Induces Histologic Remission And Deep Kidney Parenchymal B-Cell Depletion In Patients With Lupus Nephritis: Exploratory Analyses From The REGENCY Trial
Brad H. Rovin¹, Elsa Martins², Cary D. Austin³, Harini Raghu³, Caleb Chan³, Patrick S. Chang³, Jay P. Garg³, Valeria Alberton⁴, Mittermayer B. Santiago⁵, Gustavo Aroca-Martínez⁶, Fedra I. Palazuelos⁷, Teresa Baczkowska⁸, Jose Alfaro⁹, Jorge Ravelo-Hernandez¹⁰, Richard A. Furie¹¹, Luis F. Pinto¹², Eduardo H. Albeiro¹³, Christopher Larsen¹⁴, Bongin Yoo³, Jennifer Pulley¹⁵, Andrew Thorley³, Thomas Schindler¹⁶, Theodore A. Omachi³, William F. Pendergraft³, Betty Loflin³ and Ana Malvar¹⁷, ¹The Ohio State University, Columbus, OH, ²F. Hoffmann-La Roche Ltd, Basel-Landschaft, Switzerland, ³Genentech, Inc., CA, ⁴Pathology Unit, Fernández Hospital, Buenos Aires, Argentina, ⁵Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Bahia, Brazil, ⁶Universidad Simón Bolívar y Clínica de la Costa, Barranquilla, Colombia, ⁷Centro de Investigación y Tratamiento Reumatológico S.C, Distrito Federal, Mexico, ⁸Department of Transplantation Medicine, Nephrology and Inernal Medicine, Medical University of Warsaw, Poland, ⁹Instituto Peruano del Hueso y la Articulación, Lima, Peru, ¹⁰Clínica San Juan Bautista, Unidad de Investigación en Reumatología e Inmunología, Lima, Peru, ¹¹Division of Rheumatology, Northwell Health, NY, ¹²Internal Medicine and Rheumatology, Hospital Pablo Tobón Uribe, Colombia, ¹³Sanatorio Allende, Cordoba, Argentina, ¹⁴Arkana Laboratories, Little Rock, AR, ¹⁵Roche Products Ltd, Welwyn Garden City, England, United Kingdom, ¹⁶F. Hoffmann-La Roche Ltd, Basel, Basel-Landschaft, Switzerland, ¹⁷Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The REGENCY trial (NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at…
Abstract Number: 053 • 2026 Pediatric Rheumatology Symposium
Association between Childhood Opportunity Index and Disparities in Health Care Access and Utilization in Childhood Onset Systemic Lupus Erythematosus
Abigale Jagger¹, Elaine Yung², Hermine Brunner², Andrew Beck³, Eneida Mendonca³, Qing Duan⁴, Cole Brokamp⁴, Giya Harry⁵ and Jackeline Rodriguez-Smith², ¹Cincinnati Children's, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, ⁴Cincinnati Children's Hospital Medical Center, ⁵Brenner Children's Hospital - Wake Forest Baptist Health, Winston-Salem, NC
Background/Purpose: Disparities in pediatric health outcomes are well described. The role of social determinants of health (SDOH) in the persistence of such disparities is increasingly…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].